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Objectives: Chloroquine (CQ), after 67 years of use in Haiti, is still part of the official treatment policy for malaria.
Several countries around the world have used CQ in the past due to its low incidence of adverse events,
therapeutic efficacy, and affordability, but were forced to switch treatment policy due to the development of
widespread CQ resistance. The purpose of this paper was to compile literature on malaria treatment policies and
antimalarial drug efficacy in Haiti over 67-year period.
Methods: A systematic review of PubMed, Web of Science, and the Armed Forces Pest Management Board, was
conducted to find pertinent documents on national malaria treatment policies and antimalarial drug efficacy
studies in Haiti between 1955 and 2012. A total of 329 citations and abstracts were reviewed independently by two
researchers, of which thirty three met the final inclusion criteria of studies occurring in Haiti between 1955 and
2012 which specifically discuss malaria treatment policies and drug efficacy.
Results: Results suggest that CQ has been the predominant antimalarial drug in use from 1955 to 2012. In 2010
single dose primaquine (PQ) was added to the national treatment policy, however it is not clear whether this new
policy has been put into practice.
Conclusions: Although no widespread CQ resistance has been reported, some studies have detected low levels of
CQ resistance. Increased surveillance and monitoring for CQ resistance should be implemented in Haiti.
Keywords: Hispaniola, Haiti, Malaria treatment policy, Chemotherapy, Chloroquine, Anti-malarial drug resistance,
Plasmodium falciparum, PyrimethamineIntroduction
Malaria persists in Hispaniola despite its elimination from
other Caribbean countries [1]. It’s estimated that over 99%
of malaria cases in Haiti are caused by Plasmodium falcip-
arum with Anopheles albimanus serving as the principal
mosquito vector [2-4]. The burden of malaria is high in
Haiti, relative to its population of 10 million people, with
80% of the Haitian population living in areas where malaria
is endemic [5,6]. Historically, Haiti has under-reported the
number of malaria cases, largely due to limited resources,
inadequate surveillance and a shortage of trained personnel
[7-9]. The antimalarial chloroquine (CQ) has been relied* Correspondence: Michaelvonfricken@epi.ufl.edu
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article, unless otherwise stated.on heavily in Haiti, due to its low incidence of adverse
events, affordability, and perceived therapeutic efficacy, des-
pite the emergence of CQ resistance globally.
To better understand Haiti’s prolonged commitment
to CQ, we compiled reports and publications on malaria
chemotherapeutic policies and antimalarial resistance in
Haiti from 1955 to 2012 based on a systematic search of
historical literature. Prior to 1955, quinine was used
intermittently during periods of US occupation [10]. The
purpose of this paper is to document the history of Haiti’s
malaria treatment policies, while providing a useful refer-
ence for antimalarial drug resistance studies in Haiti.Methods
Data sources
Published studies and reports about malaria in Haiti
were identified from an electronic search of MEDLINE®/ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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A search of gray literature was carried out on the Armed
Forces Pest Management Board (AFPMB) database [11],
which contains publications and reports from the
Centers for Disease Control and Prevention (CDC),
World Health Organization (WHO), and Pan American
Health Organization (PAHO). Search terms were chosen
to capture malaria treatment policy and drug efficacy
studies in Haiti only, using a combination of simple
subject headings and term combinations, focusing on
treatment, malaria, and Haiti.
Study selection
The selection criteria of the data sources included are; 1)
reports from the period of 1955 to 2012, 2) all studies
carried out in Haiti, 3) and studies that discuss malaria.
Full text manuscripts and all citations which met the
predefined selection criteria were obtained and exam-
ined by two independent researchers. Final inclusion
and exclusion decisions were made with 100% agree-
ment between the examiners based on studies that re-
ported malaria treatment policies and drug efficacy for
final inclusion. Where duplications were observed the
most recent version of the manuscript was selected. The
year 1955 was used as a start date for analysis, because it
coincided with the Global Malaria Elimination Program
campaign in Haiti.
Results
A total of 329 citations and abstracts in the electronic
searches were found. Of these, 85 citations and abstracts
met the preliminary criteria and their full texts were
reviewed. Thirty three studies described malaria treat-
ment policies or antimalarial drug efficacy in Haiti from
1955-2012 [1,2,4,6-9,12-37].
Characteristics of included studies
Chloroquine was first introduced in Haiti in 1955, when
The Eighth World Health Assembly recommended its use
in combination with pyrimethamine (P) for the elimin-
ation of malaria. The chloroquine/pyrimethamine (CQ/P)
combination strategy was the first treatment policy switch
in Haiti replacing the previous accepted practice ofBefore 1955 1955 - 1970 
CQ mono
policy, due
Intermittent quinine use during periods  
of US Navy occupation 
CQ + pyremithamine during the 
Global Malaria Elimination Program
Figure 1 Timeline of Haitian malaria treatment policies.quinine for the treatment of malaria [38-40]. According to
the data sources, from 1955 to 1970, CQ/P was adminis-
tered in a prophylactic manner through mass drug admin-
istration (MDA) campaigns, as part of the Global Malaria
Eradication Program in Haiti [13,15,16,40]. From 1970 to
2010, the treatment for malaria switched from a combin-
ation therapy of CQ/P therapy to CQ monotherapy for
uncomplicated malaria cases [16]. In 2010 a CDC report
mentioned the addition of the transmission blocking drug
primaquine (PQ) at a single dose of 0.75 mg/kg, suggest-
ing a major change in policy [36]. All final articles (N = 33)
that we evaluated reported CQ as or part of the standard
treatment policy in Haiti. A brief summary of treatment
policies can be seen in the timeline provided (Figure 1).
Evidence for treatment resistance in Haiti
Only fourteen studies from the data sources examined
[6,9,12-19,21,26,32,35] discussed chemotherapeutic effi-
cacy or patient treatment outcome data (Table 1). Six of
these fourteen studies contained documentation of re-
sistance to CQ or P [6,16,18,19,21,32]. The first year of
reported of anti-malarial resistance, where P. falciparum
had documented pyrimethamine resistance was 1971 [16].
In 1982, a report of possible resistance to CQ treatment
was suggested [6] after a patient on CQ monotherapy had
resurgence in parasitemia on day 28 of treatment. A
follow-up in vitro test found 4/16 P. falciparum cultures
including the P. falciparum strains from the patient with
resurgent parasitemia, required CQ doses large enough
that suggested possible resistant P. falciparum parasites.
This report provided the first credible in vitro evidence of
P. falciparum resistance to CQ in Haiti [18]. In 1984, an
in vivo and in vitro study, tested for P. falciparum parasite
resistance to sulfadoxine/pyrimethamine (S/P) [19] to pro-
vide baseline data on susceptibility in the event that CQ
resistance developed in Haiti. The results indicated pa-
rasite resistance to pyrimethamine alone, but not to
sulfadoxine. Despite in vitro evidence of resistance to pyri-
methamine, all in vivo infections were susceptible to a
combination of S/P [19]. In 1985, another in vivo study to
complement the previous in vitro assay found resistance
to pyrimethamine alone [21]. More recently, a report by
Londono et al, has documented the detection of genetic1970 - 2010 2010 – 2012 
therapy becomes treatment 
 to pyremithamine resistance
CQ + single dose PQ, toreduce 
transmission by targeting gametocytes 
Table 1 Reports of treatment efficacy for malaria in Haiti
Period Sample
size







N/A Country Wide CQ/P Secondary N/A CQ PAHO. 1967 [14]
1961 N/A Country Wide CQ Secondary N/A CQ WHO. 1965 [13]
1962-
1965




N/A Petitie Goave CQ & CQ/P Secondary N/A CQ/P WHO, 1968 [15]
1971 N/A Country Wide CQ Secondary VV, P &
CG
CQ WHO, 1972 [16]
1976 N/A Country Wide N/A Secondary N/A CQ WHO, 1978 [17]
1980 N/A Country Wide CQ Secondary N/A VV CQ PAHO, 1980 [9]
1981-
1983
92 Les Cayes, Port-au-Prince, Limbe,
Gros-Morne and Jacmel
CQ Secondary VT & VV
CQ
CQ Duverseau YT, Magloire R, et al.,
1986 [6]
1982 19 Port-au-Prince CQ Secondary VT & VV
CQ
N/A Magloire R and Nguyen-dinh P,
1983 [18]
1982 18 Port-au-Prince P & S/P Primary VT & VV
P
VV S/P Nguyen-Dinh P, Zevallos-Ipenza
A, et al., 1984 [19]
1985 22 Port-au-Prince P & S/P Primary VT P VV & VT S/P Nguyen-Dinh P, Payne D, et al.,
1985 [21]








49 Leogane CQ Primary N/A PCR CQ Neuberger Zhong K, et al., 2012
[36]
Key: Chloroquine (CQ), pyrimethamine (P), chloroquine with pyrimethamine (CQ/P),sulfadoxine with pyrimethamine (S/P), in vivo susceptibility (VV), in vitro
susceptibility (VT), DNA examined for mutations via polymerase chain reaction (PCR).
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(6%) from the Artibonite Valley [32]. However, a study by
Neuberger et al, found zero of 49 infected patients to have
mutations suggestive of CQ resistance [36]. These studies
present conflicting evidence about the presence or absence
of CQ drug resistance in the populations studied, with no
definitive documentation of in vivo resistance reported.
Discussion
Following the widespread use of CQ/P from 1955-1968,
resistance to pyrimethamine was reported in Haiti in
1971 [16]. It was suggested that parasite adaptation to
pyrimethamine had occurred due to selective drug pres-
sure from the MDA campaign, which ended in 1968,
resulting in its removal from the national treatment
policy [16,19].
Haiti continued to rely predominantly on CQ as part
of the treatment for malaria in Haiti up until 2010, when
single dose PQ was added to the official policy for the
treatment of uncomplicated malaria in Haiti [2,37]. Haiti
represents a unique scenario where PQ has not been
used previously on the island due to the absence of Plas-
modium vivax, but is being introduced to specifically
block malaria transmission by targeting the adult stagePlasmodium falciparum parasites. It remains unclear
whether or not PQ has been implemented in practice,
nor have any studies examined population rates of
G6PD deficiency in Haiti, a genetic mutation that places
deficient individuals at risk of acute hemolytic anemia
when exposed to PQ.
Overall, we found the use of CQ has featured promin-
ently in the management of malaria in Haiti for decades.
While CQ resistance in many South and Central American
countries has forced these countries to change policies, the
Haitian Ministry of Health (MSPP) has continued to rely
almost entirely on CQ as the principal treatment for mal-
aria. Despite such prolonged use, our results found no
conclusive evidence of the presence or absence of CQ re-
sistance in Haiti (Table 1). However, findings from the stud-
ies that report on treatment sensitivity are lacking due to
small sample sizes [6,18,19,21,32,36], localized enrollment
[6,15,18,19,21,32,36], and missing information on patient
treatment outcomes, significantly limiting their ability to in-
fluence national treatment policies (Table 1). Ten of the
fourteen studies that make mention of drug efficacy, relied
solely on secondary sources of data, often only containing
brief comments on treatment effectiveness, which further
suggest an absence of designed drug sensitivity studies
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ies examining CQ resistance by Londono and Neuberger
gave different results about the presence of genetic markers
of CQ resistance in Haiti [32,36]. However, both studies had
small sample sizes of 79 and 48 respectively and were located
in different regions of the country. CQ resistance mutations
are emerging in Haiti, but to what extent remains unknown,
suggesting a need for increased surveillance for parasite
resistance.
Limitations
We were unable to examine gray literature from the
MSPP as most documents were lost during the 2010
earthquake. Although we excluded non-English data-
bases, we believe this omission to not be very significant,
since we relied heavily on WHO and PAHO reports,
which are based on both English and non-English data-
bases and reports. There were limited data pertaining
to treatment failures and parasite resistance, in addition
to an overall lack of reporting between 1985-2005 due to
political unrest [8,32].
Conclusions
As of 2012, the few documented reports of CQ resist-
ance in Haiti did not exceed the WHO recommended
threshold treatment failure rate of ≥ 10% [41]. However,
due to limited surveillance on drug efficacy and barriers
to patient follow up, further studies are necessary to de-
termine if rates of CQ resistance fall below this thresh-
old in Haiti. Meanwhile, Non-government organizations,
foreign aid agencies, and the Haitian MSPP should con-
sider implementing a comprehensive malaria control
program while CQ remains a viable treatment option
[32,35,36]. Other drug regimens, such as artemisinin-
based combination therapies, are part of an arsenal of
available treatment options, in the event of CQ resist-
ance. The affordable cost of CQ, and its’ low incidence
of adverse events make it an ideal treatment option on a
large scale. It is our recommendation that increased sur-
veillance and monitoring for CQ resistance be imple-
mented, due to significant gaps in data on CQ treatment
failure and resistance in Haiti. Regarding the recent
addition of PQ to the national policy, more information
is needed on how PQ is tolerated in this population,
given the absence of information on G6PD prevalence
rates, and whether or not this policy has been put into
practice in Haiti. Future studies examining transmission
rates in Haiti may generate valuable information on the
impact single dose PQ has on malaria rates, potentially
providing a template for elimination in other low trans-
mission settings globally.
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